STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.


Journal

NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166

Informations de publication

Date de publication:
28 Feb 2022
Historique:
received: 18 06 2021
accepted: 03 02 2022
entrez: 1 3 2022
pubmed: 2 3 2022
medline: 2 3 2022
Statut: epublish

Résumé

Patients with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who are prescribed ALK-tyrosine kinase inhibitors (ALK-TKIs) rarely have complete responses, with residual tumors relapsing as heterogeneous resistant phenotypes. Herein, we investigated new therapeutic strategies to reduce and eliminate residual tumors in the early treatment phase. Functional genomic screening using small guide RNA libraries showed that treatment-induced adaptive survival of ALK-rearranged lung cancer cells was predominantly dependent on STAT3 activity upon ALK inhibition. STAT3 inhibition effectively suppressed the adaptive survival of ALK-rearranged lung cancer cells by enhancing ALK inhibition-induced apoptosis. The combined effects were characterized by treatment-induced STAT3 dependence and transcriptional regulation of anti-apoptotic factor BCL-X

Identifiants

pubmed: 35228642
doi: 10.1038/s41698-022-00254-y
pii: 10.1038/s41698-022-00254-y
pmc: PMC8885877
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11

Subventions

Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 20K08516
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 19K16738
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 19H03665

Informations de copyright

© 2022. The Author(s).

Références

Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
pubmed: 15118125 doi: 10.1126/science.1099314
Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).
pubmed: 20573926 doi: 10.1056/NEJMoa0909530
Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007).
pubmed: 17625570 doi: 10.1038/nature05945
Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203 (2007).
pubmed: 18083107 doi: 10.1016/j.cell.2007.11.025
Lin, J. J., Riely, G. J. & Shaw, A. T. Targeting ALK: Precision medicine takes on drug resistance. Cancer Discov. 7, 137–155 (2017).
pubmed: 28122866 pmcid: 5296241 doi: 10.1158/2159-8290.CD-16-1123
Hida, T. et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390, 29–39 (2017).
pubmed: 28501140 doi: 10.1016/S0140-6736(17)30565-2
Peters, S. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
pubmed: 28586279 doi: 10.1056/NEJMoa1704795
Camidge, D. R. et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 379, 2027–2039 (2018).
pubmed: 30280657 doi: 10.1056/NEJMoa1810171
Shaw, A. T. et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N. Engl. J. Med. 383, 2018–2029 (2020).
pubmed: 33207094 doi: 10.1056/NEJMoa2027187
Gainor, J. F. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6, 1118–1133 (2016).
pubmed: 27432227 pmcid: 5050111 doi: 10.1158/2159-8290.CD-16-0596
Katayama, R. et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res. 20, 5686–5696 (2014).
pubmed: 25228534 pmcid: 4233168 doi: 10.1158/1078-0432.CCR-14-1511
Friboulet, L. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 4, 662–673 (2014).
pubmed: 24675041 pmcid: 4068971 doi: 10.1158/2159-8290.CD-13-0846
Yoda, S. et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 8, 714–729 (2018).
pubmed: 29650534 pmcid: 5984716 doi: 10.1158/2159-8290.CD-17-1256
Recondo, G. et al. Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clin. Cancer Res. 26, 242–255 (2020).
pubmed: 31585938 doi: 10.1158/1078-0432.CCR-19-1104
Yamada, T. et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin. Cancer Res. 18, 3592–3602 (2012).
pubmed: 22553343 doi: 10.1158/1078-0432.CCR-11-2972
Arai, S. et al. Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer. J. Thorac. Oncol. 15, 752–765 (2020).
pubmed: 31972351 doi: 10.1016/j.jtho.2020.01.001
Dagogo-Jack, I. et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin. Cancer Res. 26, 2535–2545 (2020).
pubmed: 32086345 pmcid: 7269872 doi: 10.1158/1078-0432.CCR-19-3906
Isozaki, H. et al. Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases. Cancer Res. 76, 1506–1516 (2016).
pubmed: 26719536 doi: 10.1158/0008-5472.CAN-15-1010
Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480–1486 (2014).
pubmed: 25394791 pmcid: 4388482 doi: 10.1126/science.1254721
Fukuda, K. et al. Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Cancer Res. 79, 1658–1670 (2019).
pubmed: 30737231 doi: 10.1158/0008-5472.CAN-18-2052
Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
pubmed: 20371346 pmcid: 2851638 doi: 10.1016/j.cell.2010.02.027
Bivona, T. G. & Doebele, R. C. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 22, 472–478 (2016).
pubmed: 27149220 pmcid: 5384713 doi: 10.1038/nm.4091
Kurppa, K. J. et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104–122.e12 (2020).
pubmed: 31935369 pmcid: 7146079 doi: 10.1016/j.ccell.2019.12.006
Arasada, R. R. et al. Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nat. Commun. 9, 3198 (2018).
pubmed: 30097569 pmcid: 6090531 doi: 10.1038/s41467-018-05626-2
Taniguchi, H. et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat. Commun. 10, 259 (2019).
pubmed: 30651547 pmcid: 6335418 doi: 10.1038/s41467-018-08074-0
Wang, R. et al. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nat. Commun. 11, 4607 (2020).
pubmed: 32929081 pmcid: 7490421 doi: 10.1038/s41467-020-18442-4
Nakagawa, T. et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 73, 2428–2434 (2013).
pubmed: 23382048 doi: 10.1158/0008-5472.CAN-12-3479
Tanimoto, A. et al. Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-mutant lung cancer. Clin. Cancer Res. 23, 3139–3149 (2017).
pubmed: 27986747 doi: 10.1158/1078-0432.CCR-16-2271
Shaw, A. T. et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicenter, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 18, 1590–1599 (2017).
pubmed: 29074098 pmcid: 5777233 doi: 10.1016/S1470-2045(17)30680-0
Seto, T. et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 14, 590–598 (2013).
pubmed: 23639470 doi: 10.1016/S1470-2045(13)70142-6
Shaw, A. T. & Engelman, J. A. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 2537–2539 (2014).
pubmed: 24963575 doi: 10.1056/NEJMoa1311107
Gettinger, S. N. et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 17, 1683–1696 (2016).
pubmed: 27836716 doi: 10.1016/S1470-2045(16)30392-8
Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signaling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234–248 (2018).
pubmed: 29405201 pmcid: 5858971 doi: 10.1038/nrclinonc.2018.8
Nishisaka, F. et al. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701. Cancer Sci. 111, 1774–1184 (2020).
pubmed: 32112605 pmcid: 7226286 doi: 10.1111/cas.14369
Lee, H. J. et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207–221 (2014).
pubmed: 25065853 doi: 10.1016/j.ccr.2014.05.019
Siersbæk, R. et al. IL6/STAT3 signaling hijacks estrogen receptor α enhancers to drive breast cancer metastasis. Cancer Cell 38, 412–423.e9 (2020).
pubmed: 32679107 pmcid: 7116707 doi: 10.1016/j.ccell.2020.06.007
Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798–809 (2009).
pubmed: 19851315 pmcid: 4856025 doi: 10.1038/nrc2734
Buchert, M., Burns, C. J. & Ernst, M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 35, 939–951 (2016).
pubmed: 25982279 doi: 10.1038/onc.2015.150
Tartaglia, M. et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 34, 148–150 (2003).
pubmed: 12717436 doi: 10.1038/ng1156
Zhang, X. et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc. Natl Acad. Sci. USA 104, 4060–4064 (2007).
pubmed: 17360477 pmcid: 1802729 doi: 10.1073/pnas.0611665104
Bendell, J. C. et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother. Pharmacol. 74, 125–130 (2014).
pubmed: 24819685 doi: 10.1007/s00280-014-2480-2
Wong, A. L. et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann. Oncol. 26, 998–1005 (2015).
pubmed: 25609248 doi: 10.1093/annonc/mdv026
Kim, M. J. et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 335, 145–152 (2013).
pubmed: 23402820 doi: 10.1016/j.canlet.2013.02.010
Bharadwaj, U. et al. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget 7, 26307–26330 (2016).
pubmed: 27027445 pmcid: 5041982 doi: 10.18632/oncotarget.8368
Hrustanovic, G. et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 21, 1038–1047 (2015).
pubmed: 26301689 pmcid: 4734742 doi: 10.1038/nm.3930
Case, D. A. et al. AMBER 10 (University of California, 2008).
Gerber, P. R. & Müller, K. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. J. Comput. Aided Mol. Des. 9, 251–268 (1995).
pubmed: 7561977 doi: 10.1007/BF00124456
Soga, S., Shirai, H., Kobori, M. & Hirayama, N. Use of amino acid composition to predict ligand-binding sites. J. Chem. Inf. Model. 47, 400–406 (2007).
pubmed: 17243757 doi: 10.1021/ci6002202
Corbeil, C. R., Williams, C. I. & Labute, P. Variability in docking success rates due to dataset preparation. J. Comput. Aided Mol. Des. 26, 775–786 (2012).
pubmed: 22566074 pmcid: 3397132 doi: 10.1007/s10822-012-9570-1

Auteurs

Naohiro Yanagimura (N)

Division of Medical Oncology Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Shinji Takeuchi (S)

Division of Medical Oncology Cancer Research Institute, Kanazawa University, Kanazawa, Japan. takeuchi@staff.kanazawa-u.ac.jp.
Nano Life Science Institute, Kanazawa University, Kanazawa, Japan. takeuchi@staff.kanazawa-u.ac.jp.

Koji Fukuda (K)

Division of Medical Oncology Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.

Sachiko Arai (S)

Division of Medical Oncology Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Azusa Tanimoto (A)

Division of Medical Oncology Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Akihiro Nishiyama (A)

Division of Medical Oncology Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Naohisa Ogo (N)

Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.

Hiroyuki Takahashi (H)

Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Pharmaceutical Business Division, Yakult Honsha Co. Ltd, Tokyo, Japan.

Akira Asai (A)

Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.

Satoshi Watanabe (S)

Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Toshiaki Kikuchi (T)

Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Seiji Yano (S)

Division of Medical Oncology Cancer Research Institute, Kanazawa University, Kanazawa, Japan. syano@staff.kanazawa-u.ac.jp.
Nano Life Science Institute, Kanazawa University, Kanazawa, Japan. syano@staff.kanazawa-u.ac.jp.

Classifications MeSH